Chen S.-C.Tan L.-B.LI-MIN HUANGChen K.-T.2021-06-242021-06-2420120929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862817929&doi=10.1016%2fj.jfma.2011.09.024&partnerID=40&md5=972b9be463a8fd74c5991b928fd9f37bhttps://scholars.lib.ntu.edu.tw/handle/123456789/566488Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and of diarrheal deaths in developing countries. Current vaccines (e.g., Rotarix, GlaxoSmithKline Biologicals; RotaTeq, Merck and Company) effectively reduce rotaviral gastroenteritis, emergency department visits, and hospitalizations. The tremendous burden of rotavirus-related diarrhea in children across the world continues to drive the remarkable pace of vaccine development. This review assesses the global epidemiological and economic burden of rotavirus diseases, summarizes the relevant principles of the development of rotavirus vaccines, and presents data on the efficacy and effectiveness of currently licensed vaccines in both developed and developing countries. ? 2012.Epidemiology; Gastroenteritis; Rotavirus; Rotavirus vaccine[SDGs]SDG3[SDGs]SDG17Rotavirus vaccine; child; child hospitalization; childhood disease; developed country; developing country; diarrhea; disease transmission; drug efficacy; drug formulation; drug safety; drug withdrawal; economic aspect; health program; human; immune response; immunization; immunogenicity; infant; infection control; intussusception; newborn; nonhuman; phase 3 clinical trial (topic); postmarketing surveillance; randomized controlled trial (topic); review; risk; Rotavirus; Rotavirus infection; serotype; treatment outcome; vaccination; viral gastroenteritis; virus strain; virus transmission; world health organization; Gastroenteritis; Humans; Rotavirus; Rotavirus Infections; Rotavirus Vaccines; Vaccines, Attenuatedreview10.1016/j.jfma.2011.09.024225262062-s2.0-84862817929